CN106999524B - Composition containing ginseng seed oil for preventing and treating prostatic hyperplasia - Google Patents
Composition containing ginseng seed oil for preventing and treating prostatic hyperplasia Download PDFInfo
- Publication number
- CN106999524B CN106999524B CN201580059489.2A CN201580059489A CN106999524B CN 106999524 B CN106999524 B CN 106999524B CN 201580059489 A CN201580059489 A CN 201580059489A CN 106999524 B CN106999524 B CN 106999524B
- Authority
- CN
- China
- Prior art keywords
- seed oil
- ginseng
- ginseng seed
- present
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 78
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 75
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 75
- 235000015112 vegetable and seed oil Nutrition 0.000 title claims abstract description 48
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 title claims abstract description 14
- 208000004403 Prostatic Hyperplasia Diseases 0.000 title claims abstract description 14
- 241000208340 Araliaceae Species 0.000 title claims abstract description 7
- 201000004240 prostatic hypertrophy Diseases 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 4
- 235000019198 oils Nutrition 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 6
- 238000003825 pressing Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 3
- 235000013305 food Nutrition 0.000 abstract description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 6
- 230000036541 health Effects 0.000 abstract description 4
- 230000006872 improvement Effects 0.000 abstract description 4
- 235000012000 cholesterol Nutrition 0.000 abstract description 2
- 230000007935 neutral effect Effects 0.000 abstract description 2
- 238000011084 recovery Methods 0.000 abstract description 2
- 239000013585 weight reducing agent Substances 0.000 abstract description 2
- 240000004371 Panax ginseng Species 0.000 description 72
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 239000002904 solvent Substances 0.000 description 12
- 230000027939 micturition Effects 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 239000005639 Lauric acid Substances 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000003549 soybean oil Substances 0.000 description 4
- 235000012424 soybean oil Nutrition 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 235000002789 Panax ginseng Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000000194 supercritical-fluid extraction Methods 0.000 description 3
- 238000003809 water extraction Methods 0.000 description 3
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 229940108924 conjugated linoleic acid Drugs 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229930182494 ginsenoside Natural products 0.000 description 2
- 229940089161 ginsenoside Drugs 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000000874 microwave-assisted extraction Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- CNNRPFQICPFDPO-UHFFFAOYSA-N octacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCO CNNRPFQICPFDPO-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000002137 ultrasound extraction Methods 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 229960002666 1-octacosanol Drugs 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QYIMSPSDBYKPPY-BANQPHDMSA-N 2,3-epoxysqualene Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C=C(/C)CC\C=C(/C)CCC1OC1(C)C QYIMSPSDBYKPPY-BANQPHDMSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000511582 Actinomyces meyeri Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000002791 Panax Nutrition 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 206010051482 Prostatomegaly Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- -1 drink Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000035777 life prolongation Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229940075999 phytosterol ester Drugs 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000037209 prostate health Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention relates to a composition containing ginseng seed oil, which is effective in alleviating and preventing male prostatic hypertrophy, and in addition, is useful for improving human health, such as fatigue recovery, weight reduction, cholesterol improvement, neutral fat improvement, etc., and thus can be widely used in the fields of food and medicine.
Description
Technical Field
The present invention relates to a composition containing ginseng seed oil effective for the prevention and treatment of prostatic hypertrophy in men.
Background
Ginseng (Panax ginseng c.a.meyer) is a plant belonging to the genus Panax of the family araliaceae, is a crude drug used in korea, china, japan, etc. from 2000 years ago, and is used for the purpose of disease prevention and life prolongation according to experience, and the effects and effects of ginseng known so far include: effects on the central nervous system, anticancer effects, anticancer activities, immune function regulating effects, antidiabetic effects, liver function hyperactivity improving effects, cardiovascular disorders improving effects, arteriosclerosis resisting effects, blood pressure regulating effects, climacteric disorders improving effects, effects on osteoporosis, anti-stress effects, anti-fatigue effects, antioxidant activities, anti-aging effects, etc. (latest Korean ginseng component and efficacy article, Korean ginseng tobacco institute, 56-112, 1996).
On the other hand, ginseng seeds contain about 15-26% oil (Beveridge et al 2002; Matsum oto et al 1986), and have been shown to have a fatty acid composition similar to olive oil since the content of monounsaturated fatty acid oleic acid (C18:1) is high as a main fatty acid component.
Further, it has been found that there are various phytosterols having an effect of reducing blood cholesterol, such as squalene, squalene oxide, campesterol, stigmasterol, sitosterol, etc., in ginseng seed oil, and thus the possibility of using ginseng seed oil as a functional raw material is on the rise. Further, it is reported that studies on ginseng seeds so far have been conducted including studies on the ginsenoside composition of ginseng seeds and ginseng roots (Hu et al 2008), studies on the saponin composition of ginseng seeds and ginseng pulp, comparative studies on the composition and oxidation stability of ginseng seed oil from different production places, the antioxidant effect of ginseng seeds by autoclaving, and the like, mainly studies on the ginsenoside composition of ginseng seeds and the composition of ginseng seed oil. Although studies on the food-grade value of such ginseng seed oil are continuously conducted, the results are negligible compared to studies on ginseng roots and fruits.
Disclosure of Invention
Technical problem to be solved
In view of the above, the present inventors have studied the new use of ginseng seed oil for human health, and have found that ginseng seed oil has an effective alleviating effect on prostatic hypertrophy, thereby completing the present invention. Accordingly, it is an object of the present invention to provide a composition for effectively preventing and treating prostatic hypertrophy in men, which comprises ginseng seed oil.
Technical scheme
In order to achieve the above objects, the present invention provides a composition for preventing and treating prostatic hypertrophy in men comprising ginseng seed oil as an effective ingredient.
Effects of the invention
The composition of the present invention can effectively relieve and prevent male prostatic hyperplasia, and is helpful for improving human health, such as fatigue recovery, weight reduction, cholesterol and neutral fat improvement, etc., so the composition of the present invention can be widely applied to the fields of food and medicine.
Drawings
Fig. 1 is a diagram illustrating a step of processing ginseng seed oil.
Best mode for carrying out the invention
The present invention relates to a composition containing ginseng seed oil having an effective effect on the prevention and treatment of male prostatomegaly symptoms.
The processing method of the ginseng seed oil used in the present invention is not particularly limited, and may be prepared, for example, according to the processing steps shown in fig. 1. Specifically, the method includes the following steps.
(a) Obtaining ginseng seeds from ginseng fruits; and
(b) and extracting oil from the ginseng seeds obtained in the above step to obtain ginseng seed oil.
The ginseng seeds in the step (a) comprise germinated or non-germinated ginseng seeds, can be raw ginseng seeds, and also can be ginseng seeds dried by sunlight drying or hot air drying.
The method for pressing oil from ginseng seeds in the present invention is not particularly limited, and various known methods can be used.
In one embodiment of the present invention, the ginseng seed oil according to the present invention may be obtained by a pressing method of pressing ginseng seeds in which the ginseng seeds are put into an oil press and pressed to extract useful components. In this case, the oil press for food can be used without limitation, and the oil pressing time is preferably 3 to 20 minutes, and the oil pressing is generally performed at normal temperature.
In another embodiment of the present invention, the ginseng seed oil may be extracted by a Supercritical Extraction (Supercritical Water Extraction). The supercritical extraction is performed using a supercritical fluid in a state exceeding the critical point, and the type of the supercritical fluid used is not particularly limited, and pentane, carbon dioxide, and the like can be used, and carbon dioxide can be preferably used. The type of the solvent used is not particularly limited, and in the present invention, alcohol or purified water can be preferably used as the solvent.
In another embodiment of the present invention, the ginseng seed oil may be extracted by a subcritical Water Extraction (subcritical Water Extraction). The subcritical extraction is performed using a solvent in a state of not exceeding the critical point as an extraction solvent, and the same effect as that of the supercritical extraction can be exhibited depending on the selection of the solvent, and the kind of the solvent used is not particularly limited, and in the present invention, it is preferable to use alcohol or purified water as the solvent.
In another embodiment of the present invention, the ginseng seed oil may be extracted by a microwave extraction method. The microwave extraction method is a method that can extract a desired component in a short time while reducing the solvent and saving energy to the maximum, and the kind of the solvent used is not particularly limited, and in the present invention, it is preferable to use alcohol or purified water as the solvent.
In another embodiment of the present invention, the ginseng seed oil may be extracted by an ultrasonic extraction method. The ultrasonic extraction method is a method capable of efficiently extracting an active ingredient in a short time without modification or loss of an extract, and the type of a solvent used is not particularly limited, and in the present invention, alcohol or purified water can be preferably used as the solvent.
The composition of the present invention may contain ginseng seed oil in an amount of 0.01 to 100 wt% based on the total weight of the composition, depending on the form of the composition.
In addition, the composition of the present invention can be formulated into tablets, pills, pellets
A pharmaceutical composition or a food composition in the form of capsule, granule, powder, ointment, drink, injection, or the like.
The present invention provides a pharmaceutical composition containing ginseng seed oil extract according to conventional methods. In the preparation of pharmaceutical dosage forms, the active ingredient is preferably mixed or diluted with a carrier, or enclosed within a carrier in the form of a container. When the carrier is used as a diluent, it may be a solid, semi-solid or liquid substance acting as a carrier, excipient or medium (medium) for the active ingredient. Thus, the dosage form may be in the form of tablets, pills, powders, sachets (sachets), elixirs (elixir), suspensions, emulsions, solutions, syrups, aerosols, soft or hard gelatin capsules, sterile injections, sterile powders, and the like.
Suitable carriers, excipients and diluents may be exemplified by lactose, glucose, sucrose, sorbitol, mannitol, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate and mineral oil. The dosage form may further comprise fillers, anticoagulants, lubricants, wetting agents, flavors, emulsifiers, preservatives, and the like. The compositions of the present invention may be formulated using methods well known in the art to provide rapid, sustained or delayed release of the active ingredient upon administration to a mammal.
The pharmaceutical composition of the present invention can be administered by various routes including oral, transdermal, subcutaneous, intravenous, intraperitoneal, intramuscular, topical application, patch, and ion permeation (ionophoresis), etc., wherein topical application and oral administration are preferred.
In humans, the active compound is administered in a daily dose of 1 to 100mg/kg body weight, preferably 5 to 70mg/kg body weight, and may be administered once or in several divided doses. However, the actual amount of active ingredient to be administered should be understood to be determined in view of various relevant factors such as the disease to be treated, the route of administration, the age, sex and weight of the patient, the severity of the disease, and the like. Accordingly, the amount administered is not intended to limit the scope of the invention in any way.
In addition, the present invention provides a food composition containing ginseng fruit extract according to a conventional method.
The food composition of the present invention has a liquid or solid form, and the form of the form is not particularly limited, and may be, for example, a tablet, a granule, a drink, caramel, a slimming bar (dietbar), or the like. In addition to the effective ingredients in the food compositions of various dosage forms, those skilled in the art can easily select and mix the ingredients conventionally used in this field as appropriate depending on the dosage form or the purpose of use, and when used simultaneously with other raw materials, synergistic effects are produced.
Detailed Description
The present invention will be described below with reference to the following examples and test examples. The examples and test examples are intended to illustrate the present invention in more detail, and the scope of the present invention is not limited to the scope of the following examples.
In addition, it will be apparent to those skilled in the art that various modifications and simulations can be made within the scope of the appended claims without departing from the scope of the technical idea of the present invention.
EXAMPLE 1 preparation of Ginseng seed oil
Pretreatment of ginseng seeds
Harvesting fruits of raw ginseng, and separating seeds, thereby harvesting ginseng seeds.
Preparation of ginseng seed oil
Ginseng seed oil (yield 0.5-2%) was obtained from the ginseng seeds obtained as described above by using a food oil press (DS-1500, DASAN food industry machinery, korea) for 5 minutes at room temperature.
The ginseng seed oil thus obtained was used in the following test examples.
[ test example 1]
< results of analysis of fatty acids and lipids in Ginseng seed oil >
The fatty acid and lipid class analysis results of the ginseng seed oil prepared in example 1 are as follows.
TABLE 1
| Composition (I) | Content (wt.) |
| Lauric acid (mg/100g) | 2.5 |
| Phytosterol (mg/100g) | 7.38 |
| Phytosterol ester (mg/100g) | 10.5 |
| Conjugated linoleic acid (mg/100g) | 1.4 |
| Trans-9, trans-11 conjugated linoleic acid (mg/100g) | 1.04 |
| Octacosanol (mg/100g) | 0.005 |
| Phospholipid (mg/100g) | 20.21 |
| Gamma-linolenic acid (mg/100g) | 1.36 |
As shown in the results of table 1, fatty acids and lipids were detected in the ginseng seed oil of the present invention.
[ test example 2] quality of life evaluation questionnaire related to prostatic hypertrophy (BPH QoL-k1)
In order to evaluate the quality of life related to prostatic hypertrophy, questionnaires are being conducted in Korea on the following items (questionnaires on quality of life related to prostatic hypertrophy are developed: reliability and feasibility verification, Dahan urology Association, Vol.41, 2000, 35-46).
(1) It is inconvenient due to frequent urination at ordinary times.
(2) It is inconvenient to urinate when sleeping at night.
(3) After urination, the urine still drips to wet the underwear, which is inconvenient.
(4) It is inconvenient for the patient to urinate in time when the patient is in an urgent state.
(5) It is inconvenient because the urine still has a feeling of not being discharged.
(6) It is inconvenient due to difficulty in holding urine.
(7) It is inconvenient because of the thin urine flow.
(8) It is inconvenient because of difficulty in urination when the body is tired.
(9) Inconvenience is caused by the heavy and stiff feeling of the genital area.
(10) After urination, the abdomen still feels heavy and stabbing and inconvenient.
(11) Worry about frequent urination without drinking.
(12) Work is affected by the frequency of urination.
(13) It is inconvenient for frequent urination during long-distance travel.
(14) The frequency of the toilet is more than that of others, so that the toilet is inconvenient.
(15) It is inconvenient to go to mountaineering or carry out field activities.
(16) The frequent urination can cause a feeling of mental strain.
(17) And feel uneasy and tense for a long time of riding.
(18) It is difficult to go to deep sleep.
(19) The product is not active for every thing and has no desire.
(20) It is difficult to concentrate on an event.
(21) Spleen qi often develops without any particular cause.
(22) The worry or worry about everything is high.
(23) It is difficult to attend religious activities such as church and temple because of frequent urination.
(24) The user feels a lot of trouble in joining the party with other people.
(25) There is no confidence whether the healthy life can be passed in the later years.
(26) Worry about their health.
(27) Fear that the condition will worsen with age and require continued treatment.
(28) Fear that the disease turns into malignant.
(29) Fear that urination will not be possible if the symptoms further worsen in the future.
(30) The sexual desire is reduced from before.
(31) It is difficult to erect.
(32) Even if erect, it will immediately atrophy or fail to quickly ejaculate.
(33) There seems to be something inadequate and no confidence in sex.
(34) Fatigue is often felt.
(35) It is difficult to move freely due to physical strength reduction.
To correspond to "0: no inconvenience at all; 1: there is little inconvenience; 2: can be tolerated; 3: inconvenience; 4: is very inconvenient; 5 cannot be tolerated. "the above 35 items were examined for score, and the total score was summed up to evaluate the quality of life associated with prostatic hypertrophy.
60 men over 40 years old who were not normally affected by urination were subjected to a first questionnaire to prepare a diagnosis questionnaire, and the above 60 men were divided into 3 groups of 20 per group. For group 1, the ginseng seed oil of example 1 was put into 1ml straw containers, and taken 28 times with milk. Namely, the standardized ginseng seed oil (ginseng seed oil intake group) was taken 1 time and 28ml daily. In addition, for the other group, lauric acid was taken up for comparison. Specifically, 2.5mg of lauric acid was dissolved in 1ml of soybean oil, and 28ml of soybean oil in which lauric acid was dissolved (i.e., the total lauric acid content was 70mg, which is the same amount as that of lauric acid contained in 28ml of ginseng seed oil) was taken 1 time per day (lauric acid intake group). In addition, 28ml of soybean oil containing no other effective ingredient was ingested 1 time per day for the other group (non-ingested group). After about 4 weeks of ingestion as described above, diagnostic questionnaires were again prepared to compare before and after ingestion of ginseng seed oil, lauric acid, or soybean oil.
The results are shown in table 2 below as changes in the evaluation scores of the diagnostic questionnaire (N ═ 60).
TABLE 2
As shown in table 2 above, the test subjects who ingested the ginseng seed oil were found to have a lower evaluation score of the questionnaire, and the degree of improvement was significantly higher than the case of ingesting lauric acid, which is known to be beneficial for prostate health by relaxing the prostate smooth muscle to alleviate the symptoms of prostate hypertrophy. Therefore, it was confirmed that the ingestion of ginseng seed oil improved the symptoms of prostatic hypertrophy.
The following is a description of an example of a dosage form of the composition of an embodiment of the present invention, but the present invention may be applied to other various dosage forms, which are only for specific purposes and are not intended to limit the present invention.
Formulation example 1 ginseng seed oil 100% concentrate (extract)
The ginseng seed oil of example 1 was concentrated to a solid content of 20% or more, and was aged at low temperature to prepare a 100% concentrate product in a liquid form.
[ formulation example 2] Soft Capsule
100mg of the ginseng seed oil of example 1, 0.8mg of palm oil, 0.48mg of a vegetable hardened oil, 2.4mg of yellow beeswax and 3.6mg of lecithin were mixed and filled according to a conventional method to prepare a soft capsule.
[ dosage form example 3] tablet
160mg of the ginseng seed oil of example 1, 200mg of glucose and 196mg of dextrin were mixed and granulated by a fluid bed dryer, and then 7mg of sugar ester (sugar ester) was added and tabletted by a tabletting machine to prepare tablets.
[ dosage form example 4] preparation of pellets
Pellets were prepared by mixing 0.9g of the ginseng seed oil of example 1, 0.3g of sugar, 1.91g of starch and 0.56g of glycerin, and using a pellet mill.
[ formulation example 5] granules
160mg of the ginseng seed oil of example 1, 200mg of glucose, and 196mg of dextrin were mixed, granulated in a fluidized bed dryer, and filled in a pouch to prepare granules.
[ formulation example 6] beverage
110mg of the ginseng seed oil of example 1, 10g of glucose and 2g of citric acid were mixed, and then 188g of purified water was added to fill bottles to make 200ml per bottle. After filling the bottle, the bottle was sterilized at 90 ℃ for 2 to 3 hours to prepare a beverage.
Claims (3)
1. Use of a composition comprising ginseng seed oil as an active ingredient for the preparation of a medicament for the prevention and treatment of prostatic hypertrophy, wherein said ginseng seed oil is obtained by pressing oil from ginseng seeds.
2. Use according to claim 1, wherein the ginseng seed oil is present in an amount of 0.01 to 100% by weight relative to the total weight of the composition.
3. Use according to claim 1 or 2, wherein the composition is a pharmaceutical composition.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140149716A KR102273967B1 (en) | 2014-10-31 | 2014-10-31 | Composition for preventing and treating prostatic hypertrophy containing ginseng seed oil |
| KR10-2014-0149716 | 2014-10-31 | ||
| PCT/KR2015/011246 WO2016068547A1 (en) | 2014-10-31 | 2015-10-23 | Composition containing ginseng seed oil for prevention and treatment of prostatic hypertrophy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106999524A CN106999524A (en) | 2017-08-01 |
| CN106999524B true CN106999524B (en) | 2021-01-15 |
Family
ID=55857807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580059489.2A Active CN106999524B (en) | 2014-10-31 | 2015-10-23 | Composition containing ginseng seed oil for preventing and treating prostatic hyperplasia |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP6615200B2 (en) |
| KR (1) | KR102273967B1 (en) |
| CN (1) | CN106999524B (en) |
| WO (1) | WO2016068547A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210121892A (en) * | 2020-03-31 | 2021-10-08 | (주)아모레퍼시픽 | Composition comprising ginseng seed oil |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU23256A1 (en) * | 2003-03-20 | 2008-01-24 | Dalmer Lab Sa | EXTRACT OBTAINED FROM ROYSTONEA REGIA FRUITS USED AGAINST PROSTATE HYPERPLASIA AND PROSTATITIS |
| CN101134054A (en) * | 2006-08-30 | 2008-03-05 | 北京欧纳尔生物工程技术有限公司 | Pharmaceutical composition for improving urination disorders caused by BPH and method for making the same |
| CN102065836A (en) * | 2008-06-13 | 2011-05-18 | 株式会社爱茉莉太平洋 | External preparation composition for skin comprising ginseng flower or ginseng seed extracts |
| KR101280300B1 (en) * | 2011-05-04 | 2013-07-01 | 이현기 | Health-aid food used the ginseng seed oil by main raw material |
| KR101790131B1 (en) * | 2011-09-16 | 2017-10-25 | 초임계연구소 주식회사 | Process for Preparing Ginseng seed Oil of High Oxidative Stability and Low Color with Supercritical Fluid |
| KR101429820B1 (en) * | 2012-10-31 | 2014-08-12 | 세명대학교 산학협력단 | Extract of ginseng seed, composition or oil having the same, and preparing method thereof |
| KR101452320B1 (en) * | 2014-03-11 | 2014-10-22 | 주식회사 벤스랩 | FERMENTED CAMELLIA JAPONICA SEED OIL INHIBITING 5-α REDUCTASE FOR IMPROVEMENT OF BENIGN PROSTATIC HYPERPLASIA AND ALOPECIA |
-
2014
- 2014-10-31 KR KR1020140149716A patent/KR102273967B1/en active IP Right Grant
-
2015
- 2015-10-23 CN CN201580059489.2A patent/CN106999524B/en active Active
- 2015-10-23 WO PCT/KR2015/011246 patent/WO2016068547A1/en active Application Filing
- 2015-10-23 JP JP2017523344A patent/JP6615200B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016068547A1 (en) | 2016-05-06 |
| JP6615200B2 (en) | 2019-12-04 |
| KR102273967B1 (en) | 2021-07-08 |
| CN106999524A (en) | 2017-08-01 |
| KR20160052001A (en) | 2016-05-12 |
| JP2018500285A (en) | 2018-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101498780B1 (en) | Composition for preventing or treating hangover | |
| CN105358168B (en) | Composition having function of relieving premenstrual syndrome and dysmenorrhea | |
| WO2012097578A1 (en) | Pharmaceutical composition for spleen and stomach caring and preparation method therefor | |
| WO2006001654A1 (en) | Composition containing ginseng extract comprising saponin derivatives isolated fromginseng radix and ginseng for preventing and treating scratching diseases | |
| KR101687982B1 (en) | Composition for improving sexual functionality having effects of increasing of the number of sperm and protection of environmental hormone and manufacturing method thereof | |
| EP2891496B1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING COMPLEX EXTRACT OF CRATAEGI FRUCTUS and CITRI PERICARPIUM AS AN ACTIVE INGREDIENT FOR TREATING OR PREVENTING OBESITY OR LIPID-RELATED METABOLIC DISEASES | |
| KR101729003B1 (en) | Composition For Preventing or Treating Gout Containing Extracts or Fermentation Metabolites of Dendropanax morbiferus | |
| JP7161064B2 (en) | Composition for prevention, treatment or improvement of male menopausal syndrome containing elderberry extract as an active ingredient | |
| KR20160141027A (en) | Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder | |
| CN106999524B (en) | Composition containing ginseng seed oil for preventing and treating prostatic hyperplasia | |
| KR20100129571A (en) | Functional composition for improvement of sex and food having the same | |
| JP6762946B2 (en) | Compositions for the prevention, amelioration, or treatment of burnout syndrome | |
| WO2014123305A2 (en) | Composition for preventing, improving or treating male climacteric containing dandelion extract or composite extract containing dandelion as active ingredient | |
| KR100522579B1 (en) | Pharmaceutical composition comprising the extracts of scutellaria root and schizandra fruit mixture thereof having an effect of restraint stress | |
| JP2011510016A (en) | Combination therapy composed of actinidia and steroids and their use | |
| KR101460126B1 (en) | Composition for preventing and improving sex hormone-related disease and symptoms comprising dandelion extract or dandelion containing multiple extract as an active ingredient | |
| KR101119410B1 (en) | Foeniculum vulgar extracts compositions for treating or preventing inflammatory diseases | |
| JP2004352626A (en) | Anticholesterol agent containing plant-derived component | |
| JP2004323439A (en) | Composition for ameliorating blood viscosity | |
| KR20160082824A (en) | Composition for Preventing Obesity and Improving Lipid Metabolism Using Active Ingredient with the Mixture of Extract of Rubus Occidentalis and Red Ginseng Fermentation | |
| CN112057536B (en) | Traditional Chinese medicine composition for preventing or/and treating dyslipidemia and application thereof | |
| CN101816708A (en) | Treat rheumatismal Chinese medicine composition and preparation method thereof | |
| JP2017039675A (en) | Lipase inhibitor | |
| CN117882864A (en) | Composition for preventing Alzheimer disease and preparation method and application thereof | |
| CN112089783A (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing or/and treating obesity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |